AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01216163
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of acetaminophen (1000mg)
Trial: NCT01216163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of placebo
Trial: NCT00152009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04618263
Drug: GATE-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist
Trial: NCT00993824
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02733705
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl 0.5 mcg/kg ideal BW
Trial: NCT01992705
Drug: -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
Trial: NCT04351243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT01156194
Drug: Homeopathy 1
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arnica montana C6 and Bellis perennis C6
Trial: NCT01156194
Drug: Homeopathy 2
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arnica montana C30 and Bellis perennis C30
Trial: NCT01156194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: globule identical to true homeopathy comparators
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoarthritis, flexible dose depending on patients' pain relief
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post surgical neurophatic pain, flexible dose depending on patients' pain relief
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post traumatic neuropathic pain, flexible dose depending on patient pain relief
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Cord Injury, flexible dose depending on patients' pain relief
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic Neuropathy, flexible dose depending on patients' pain relief
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post stroke pain, flexible dose depending on patients' pain relief
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low back pain, flexible dose depending on patients' pain relief
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
Trial: NCT00642837
Drug: Tramadol/acetaminophen
RxNorm normalized name: TRAMADOL/ACETAMINOPHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
Trial: NCT04146896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally
Trial: NCT00006115
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006115
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006115
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006115
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02873819
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
Trial: NCT02873819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
Trial: NCT00002658
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002658
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00009581
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00734253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules taken twice a day for 1-year
Trial: NCT02746042
Drug: Sinupret extract coated tablets
RxNorm normalized name: Plantago indica seed coat extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 coated tablet 3 times a day for 16-weeks (1-1-1)
Trial: NCT02746042
Drug: Placebo coated tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 coated tablet 3 times a day for 16-weeks (1-1-1)
Trial: NCT04191681
Drug: Usual care (standard-of-care) arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
Trial: NCT02935673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of matching placebo.
Trial: NCT03681067
Drug: GSK1070806
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
Trial: NCT01773707
Drug: CTLA4-Ig (Abatacept)
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as 30 minute IV infusion
Trial: NCT01773707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline given as 30 minute IV infusion
Trial: NCT01255709
Drug: Arm T1: Primatene Mist HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
Trial: NCT01255709
Drug: Arm T2: Primatene Mist HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
Trial: NCT01255709
Drug: Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
Trial: NCT01615354
Drug: Microgynon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses
Trial: NCT01615354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses
Trial: NCT01280734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet or encapsulated tablet at 23:00
Trial: NCT02468102
Drug: Standard of care drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Trial: NCT01268202
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40mg/day during 12 months
Trial: NCT00911716
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02995850
Drug: CRS+HIPEC
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Ib~   * Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~2. II~   ① CRS If PCI \<12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~   If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI \<12, CRS will be done.~   ② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~   ③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~   ④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks.
Trial: NCT00801528
Drug: Ropivacaine, Diclofenac, Water for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
Trial: NCT00997152
Drug: JTT-654 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT02391259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: contains no active drug
Trial: NCT02269072
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cream applied daily for two weeks
Trial: NCT02269072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert cream otherwise identical to testosterone cream applied daily for two weeks
Trial: NCT00391651
Drug: TMP/SMX DS twice daily x 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP/SMX DS twice daily x 3 days
Trial: NCT04291456
Drug: Minocycline 100mg
RxNorm normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-arm trial of minocycline 100 mg twice daily
Trial: NCT03026933
Drug: KI1107 4 Capsules, QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KI1107 4 Capsules
Trial: NCT03026933
Drug: Rosuvastatin Calcium 20 MG, QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin Calcium 20mg, QD
Trial: NCT03204058
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis followed by placement of placebo gel
Trial: NCT03204058
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral prophylaxis followed by placement of rosuvastatin gel
Trial: NCT01880359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00817375
Drug: SSRI treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
Trial: NCT00817375
Drug: non-SSRI treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Trial: NCT01370005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 10773 low dose
Trial: NCT02933645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
Trial: NCT01370005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 10773 high dose
Trial: NCT01771822
Drug: Ibuprofen 5% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
Trial: NCT02294539
Drug: Losartan 50mg/Hydrochlorothiazide 12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, 1T, PO medication
Trial: NCT00930631
Drug: [3H] BMS747158
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus intravenous injection of \[3H\] BMS747158
Trial: NCT01466517
Drug: Alivium®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
Trial: NCT01466517
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
Trial: NCT02294539
Drug: Losartan 100mg/Hydrochlorothiazide 25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, 1T, PO medication
Trial: NCT03581123
Drug: Standard Medical Care (SMC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
Trial: NCT01202487
Drug: LET - Lidocaine Epinephrine Tetracaine
RxNorm normalized name: epinephrine / lidocaine / tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
Trial: NCT03672188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
Trial: NCT02161588
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration as tablets.
Trial: NCT03701022
Drug: SHR1210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
Trial: NCT02714998
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose systemic methotrexate administration (50 mg/m2)
Trial: NCT02502188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00267956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
Trial: NCT01093651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo for 4-6 months
Trial: NCT02958722
Drug: physiological solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00599625
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg administered daily for 6 consecutive weeks
Trial: NCT03804866
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
Trial: NCT03804866
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles
Trial: NCT02256553
Drug: Rescue Medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
Trial: NCT02385539
Drug: The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
Trial: NCT04471415
Drug: DRP-104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week
Trial: NCT04391439
Drug: Intravenous Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00773058
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: hydrocortisone 100mg q8h
Trial: NCT00773058
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 100ml q8h
Trial: NCT02212275
Drug: Dextromethophan
RxNorm normalized name: THROAT LOZENGE W/BENZOCAINE,DEXTROMETHOPHAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
Trial: NCT01180400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, twice daily for 8 weeks
Trial: NCT05070468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
Trial: NCT00442559
Drug: inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
Trial: NCT00668057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg matching placebo
Trial: NCT00668057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg matching placebo
Trial: NCT00668057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg matching placebo
Trial: NCT05533788
Drug: ABSK091 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABSK091 tablet which is being developed for the treatment of patients with advanced solid tumors
Trial: NCT03507452
Drug: BAY2287411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days).
Trial: NCT03507452
Drug: BAY2287411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation.
Trial: NCT00337246
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00098735
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00157209
Drug: Single low dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
Trial: NCT02299011
Drug: Biomatrix drug eluting stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomatrix Flex drug eluting stent
Trial: NCT01887002
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-2952 Matching Placebo every day for 2 weeks
Trial: NCT00554814
Drug: Bledilait Biofer®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bledilait Biofer® 2 mg/100 kcal
Trial: NCT00554814
Drug: Blédilait Biofer®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blédilait Biofer® milk (1,1mg/100kcal)
Trial: NCT00003049
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003049
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes